These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23528446)

  • 1. A review on estimation of stochastic differential equations for pharmacokinetic/pharmacodynamic models.
    Donnet S; Samson A
    Adv Drug Deliv Rev; 2013 Jun; 65(7):929-39. PubMed ID: 23528446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations.
    Tornøe CW; Overgaard RV; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2005 Aug; 22(8):1247-58. PubMed ID: 16078134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population stochastic modelling (PSM)--an R package for mixed-effects models based on stochastic differential equations.
    Klim S; Mortensen SB; Kristensen NR; Overgaard RV; Madsen H
    Comput Methods Programs Biomed; 2009 Jun; 94(3):279-89. PubMed ID: 19268387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-linear mixed-effects models with stochastic differential equations: implementation of an estimation algorithm.
    Overgaard RV; Jonsson N; Tornøe CW; Madsen H
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):85-107. PubMed ID: 16175312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics.
    Olafsdottir HK; Leander J; Almquist J; Jirstrand M
    AAPS J; 2018 Aug; 20(5):88. PubMed ID: 30069613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stochastic nonlinear mixed effects: a metformin case study.
    Matzuka B; Chittenden J; Monteleone J; Tran H
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):85-98. PubMed ID: 26585899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperparameter estimation using stochastic approximation with application to population pharmacokinetics.
    Mentré F; Mallet A; Steimer JL
    Biometrics; 1988 Sep; 44(3):673-83. PubMed ID: 3203126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum likelihood estimation of a time-inhomogeneous stochastic differential model of glucose dynamics.
    Picchini U; Ditlevsen S; De Gaetano A
    Math Med Biol; 2008 Jun; 25(2):141-55. PubMed ID: 18504247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grey-box modelling of pharmacokinetic/pharmacodynamic systems.
    Tornøe CW; Jacobsen JL; Pedersen O; Hansen T; Madsen H
    J Pharmacokinet Pharmacodyn; 2004 Oct; 31(5):401-17. PubMed ID: 15669774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using spline-enhanced ordinary differential equations for PK/PD model development.
    Wang Y; Eskridge K; Zhang S; Wang D
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):553-71. PubMed ID: 18989761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Density-based Monte Carlo filter and its applications in nonlinear stochastic differential equation models.
    Huang G; Wan J; Chen H
    Comput Biol Med; 2013 Feb; 43(2):135-43. PubMed ID: 23246109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.
    Piotrovsky VK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A4S: a user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation.
    Germani M; Del Bene F; Rocchetti M; Van Der Graaf PH
    Comput Methods Programs Biomed; 2013 May; 110(2):203-14. PubMed ID: 23182621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach.
    Nong A; Krishnan K
    Regul Toxicol Pharmacol; 2007 Jun; 48(1):93-101. PubMed ID: 17367907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian analysis of growth curves using mixed models defined by stochastic differential equations.
    Donnet S; Foulley JL; Samson A
    Biometrics; 2010 Sep; 66(3):733-41. PubMed ID: 19912169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
    Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
    Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.